Business
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025
Palatin Technologies, Inc. (OTC PINK: PTNT), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor system, today presented new data from the Phase 3 MELODY-1 study at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The updated responder analyses highlight PL9643's rapid onset of action, broad and statistically significant efficacy, and complete symptom resolution across multiple endpoints in patients with dry eye dise
About this update from Palatin Technologies, Inc.
[{"type":"text","content":"Updated Phase 3 analysis highlights PL9643 as a potential first-in-class treatment achieving full symptom resolution.","length":122,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Responder analyses demonstrate statistically significant symptom resolution across multiple endpoints in PL9643-treated patients compared to placebo. ","length":149,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"6 of 13 symptom endpoints reached statistical significance (p<0.05).","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"This level of symptom clearing has not been demonstrated by any currently approved dry eye disease therapy.","length":107,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":178,"olType":false}]},{"val":[{"type":"text","content":"Symptom resolution was observed as early as two weeks and continued through week 12 without plateau.","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"PL9643 significantly improved clinical signs for staining measures, indicating potential to protect the ocular surface.","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"PL9643 was well tolerated, with adverse event rates comparable to or better than vehicle.","length":89,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":635,"olType":false},{"type":"text","content":"CRANBURY, N.J., May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor system, today presented new data from the Phase 3 MELODY-1 study at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The updated responder analyses highlight PL9643's rapid onset of action, broad and statistically significant efficacy, and complete symptom resolution across multiple endpoints in patients with dry eye disease (DED).","length":558,"tagName":"p"},{"type":"image","alt":"Palatin Technologies, Inc.","displaySize":"","headline":null,"caption":"Palatin Technologies, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":345,"url":"https://media.zenfs.com/en/prnewswire.com/965a03f88317259fbf5e1a6eed8134bc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AQfwD723Z4IUxlX8GukUvg--/YXBwaWQ9aGl...